Literature DB >> 4078865

The genetic control of phenformin 4-hydroxylation.

R R Shah, D A Evans, N S Oates, J R Idle, R L Smith.   

Abstract

Previously published results of phenformin 4-hydroxylation in 195 unrelated white British volunteers and 87 family members of 27 randomly selected probands have been subjected to genetic analysis. The results clearly show that about 9% of this population has a genetically determined defect in carrying out this oxidation reaction. The character for the defect is inherited in a Mendelian autosomal recessive fashion. The polymorphism shows a substantial degree of dominance.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4078865      PMCID： PMC1049479          DOI： 10.1136/jmg.22.5.361

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


  17 in total

1.  The fate of biguanides in man.

Authors:  R Beckmann
Journal:  Ann N Y Acad Sci       Date:  1968-03-26       Impact factor: 5.691

2.  Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation.

Authors:  N S Oates; R R Shah; J R Idle; R L Smith
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

3.  Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin.

Authors:  B E Wiholm; G Alvan; L Bertilsson; J Sawe; F Sjöqvist
Journal:  Lancet       Date:  1981-05-16       Impact factor: 79.321

4.  On the urinary disposition of phenformin and 4-hydroxy-phenformin and their rapid simultaneous measurement.

Authors:  N S Oates; R R Shah; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1980-10       Impact factor: 3.765

5.  Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.

Authors:  J R Idle; A Mahgoub; T P Sloan; R L Smith; C O Mbanefo; E A Bababunmi
Journal:  Cancer Lett       Date:  1981-02       Impact factor: 8.679

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  Polymorphic hydroxylation of perhexiline maleate in man.

Authors:  R G Cooper; D A Evans; E J Whibley
Journal:  J Med Genet       Date:  1984-02       Impact factor: 6.318

Review 9.  Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.

Authors:  D Luft; R M Schmülling; M Eggstein
Journal:  Diabetologia       Date:  1978-02       Impact factor: 10.122

10.  Correlation of plasma phenformin concentration with metabolic effects in normal subjects.

Authors:  M Nattrass; K Sizer; K G Alberti
Journal:  Clin Sci (Lond)       Date:  1980-02       Impact factor: 6.124
View more
  4 in total

Review 1.  The Mechanism of Action of Biguanides: New Answers to a Complex Question.

Authors:  Laura Di Magno; Fiorella Di Pastena; Rosa Bordone; Sonia Coni; Gianluca Canettieri
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

2.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Comparative tolerability profiles of oral antidiabetic agents.

Authors:  A J Krentz; R E Ferner; C J Bailey
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

4.  Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.

Authors:  Matthew J Martin; Cath Eberlein; Molly Taylor; Susan Ashton; David Robinson; Darren Cross
Journal:  Oncotarget       Date:  2016-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.